tradingkey.logo

Aurora Cannabis Q1 revenue up 17%, adjusted EBITDA rises 209%

ReutersAug 6, 2025 11:38 AM


Overview

  • Aurora Cannabis fiscal Q1 2026 rev rises 17%, driven by medical cannabis growth

  • Adjusted EBITDA for fiscal Q1 grows 209%, reflecting strong operational performance

  • Co maintains strong balance sheet with $186 mln cash and debt-free cannabis business


Outlook

  • Aurora expects Q2 2026 net revenue to grow year-over-year

  • Company anticipates 8%-12% growth in Global Medical Cannabis segment

  • Aurora sees adjusted gross margins rising by 250-475 basis points

  • Company expects significant cash outflows to impact Q2 2026 free cash flow


Result Drivers

  • MEDICAL CANNABIS - 37% increase in global medical cannabis revenue driven by higher sales in Australia, Germany, Poland, and the UK

  • INTERNATIONAL GROWTH - 85% growth in international medical cannabis revenue, now accounting for 57% of global medical cannabis net revenue

  • PLANT PROPAGATION - 4% revenue increase due to organic growth and expanded product offerings, despite inventory write-offs


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

C$64.80 mln

Q1 Adjusted EBITDA

C$10.80 mln

Q1 Adjusted Gross Margin

52.0%

Q1 Adjusted Gross Profit

C$49 mln

Q1 Net Income from Cont Ops

-C$19.40 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nCNWvWTKZa

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI